# Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

> **NCT05513612** · PHASE1 · WITHDRAWN · sponsor: **Shanghai Pudong Hospital**

## Conditions studied

- Acute Myeloid Leukemia (AML)
- B-cell Non-Hodgkin's Lymphoma (B-NHL)
- Multiple Myeloma (MM)
- T-Cell Leukemia/Lymphoma, Adult
- B-cell Acute Lymphoblastic Leukemia (B-ALL)

## Interventions

- **BIOLOGICAL:** Autologous CAR-T cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05513612
- **Lead sponsor:** Shanghai Pudong Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-08-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study is not initiated and we want it to be withdrawn.
- **Last updated:** 2023-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05513612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05513612, "Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05513612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*